Tresiba Cost in Michigan 2026: Prices, Insurance, Medicaid, and Savings Options

What Does Tresiba Actually Cost in Michigan in 2026?

The Novo Nordisk wholesale list price for Tresiba sits near $510 per month in 2026, but list price is rarely what Michigan patients pay at the pharmacy counter. Retail cash-pay prices across Michigan pharmacies average about $35 per month when patients use GoodRx, NeedyMeds, or the Novo Nordisk savings program. The gap between list price and actual cash price reflects manufacturer rebates, pharmacy benefit manager contracts, and patient assistance layering.

Tresiba is a long-acting basal insulin analog. It contains insulin degludec, which forms multi-hexamer chains after subcutaneous injection and releases monomers slowly over more than 42 hours [1]. That ultra-long half-life gives it a flatter, more stable action profile than insulin glargine U-300 or insulin detemir. The FDA approved Tresiba on September 25, 2015, for adults with type 1 and type 2 diabetes, and later extended approval to pediatric patients aged 1 year and older [2].

Clinically, the DEVOTE trial (N=7,637, 2-year follow-up) compared insulin degludec to insulin glargine U-100 in patients with type 2 diabetes at high cardiovascular risk. Tresiba was non-inferior to glargine on major adverse cardiovascular events (MACE: 8.5% vs. 9.3%; HR 0.91 to 95% CI 0.78, 1.06; P<0.001 for non-inferiority) and produced 40% fewer severe hypoglycemic episodes (rate ratio 0.60 to 95% CI 0.48, 0.76; P<0.001) [3]. That hypoglycemia reduction is a meaningful clinical reason providers in Michigan prefer it over older basal insulins for high-risk patients.

Because no FDA-approved biosimilar of insulin degludec exists as of 2026, Michigan patients have no true generic alternative through standard retail channels. The only lower-cost analog options involve compounded formulations or patient assistance programs described later in this article.

Michigan Medicaid and Tresiba: Coverage Rules and Prior Authorization

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers Tresiba for both type 1 and type 2 diabetes, but the drug requires prior authorization (PA) before the claim will process. Without a completed PA, the pharmacy will reject the claim even if the prescriber has a valid order on file.

To obtain PA approval in Michigan Medicaid, prescribers typically must document [4]:

• A confirmed diagnosis of type 1 or type 2 diabetes mellitus with an ICD-10 code (E10.x or E11.x)
• Clinical rationale for a long-acting basal insulin (most plans accept A1C above target or documented hypoglycemia risk)
• A trial of, or contraindication to, a preferred formulary basal insulin such as insulin glargine (Lantus, Basaglar) or insulin detemir (Levemir)

The American Diabetes Association (ADA) 2024 Standards of Care state that "insulin degludec may be preferred for patients with recurrent severe hypoglycemia or those who require dosing flexibility" [5]. That ADA language often satisfies the clinical-rationale section of a Michigan Medicaid PA form.

PA approvals are typically granted for 12 months and renewable. If denied, the prescriber can appeal with the DEVOTE hypoglycemia data cited above [3]. Michigan's Medicaid managed care organizations (MCOs), including Molina Healthcare of Michigan, Blue Cross Complete of Michigan, and McLaren Health Plan, each administer their own PA process, so turnaround times vary from 24 hours to 10 business days.

Patients enrolled in the Healthy Michigan Plan who are dually eligible for Medicare should also check Part D formularies, because coverage may shift to Medicare as the primary payer. The Centers for Medicare and Medicaid Services (CMS) Part D formulary finder at medicare.gov allows plan-specific tier lookup by zip code [6].

Which Commercial Insurance Plans Cover Tresiba in Michigan?

Most large commercial insurers operating in Michigan place Tresiba on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on the plan year and formulary version. Tier placement directly determines your copay or coinsurance.

Blue Cross Blue Shield of Michigan (BCBSM) individual and group plans generally list Tresiba as a Tier 3 preferred brand with a 30-day copay ranging from $45 to $90 after deductible. Priority Health plans in Michigan vary by product line; their HMO products may require step therapy through insulin glargine before approving Tresiba. HAP (Health Alliance Plan) formularies similarly require documentation of glargine trial in most plan designs.

Employer-sponsored plans that use Express Scripts or CVS Caremark as their pharmacy benefit manager (PBM) may have negotiated formulary positioning that differs from the insurer's standard list. A 2022 analysis in JAMA Internal Medicine found that net prices after rebates for insulin products differed by as much as 40% from list prices, with basal analogs like degludec subject to the largest rebate offsets [7]. In practical terms, your actual copay depends on your specific plan document, not the drug's list price.

Under the Inflation Reduction Act, Medicare Part D insulin costs are capped at $35 per month for each covered insulin beginning January 1, 2023. Michigan residents on Medicare who use Tresiba as their covered basal insulin pay no more than $35 per 30-day supply regardless of plan tier [8]. This cap does not apply to commercial insurance or Medicaid.

Always verify current formulary status by calling the member services number on your insurance card or using your plan's online drug-lookup tool before filling a new prescription. Formularies change on January 1 of each plan year.

How the Novo Nordisk Savings Card Works in Michigan

Novo Nordisk operates a branded savings card program for Tresiba that reduces monthly costs for eligible commercially insured patients in Michigan. As of 2026, eligible patients pay no more than $99 per month for up to 3 FlexTouch pens per fill under the standard savings card, though Novo Nordisk periodically adjusts program limits.

The savings card is available at NovoCare.com and at participating Michigan pharmacies including CVS, Walgreens, Meijer, Kroger, and Rite Aid. Patients who are uninsured may qualify for Novo Nordisk's Patient Assistance Program (PAP), which provides Tresiba at no cost to patients whose household income is at or below 400% of the federal poverty level [9].

Key eligibility rules for the savings card:

• Must have commercial (private) insurance; Medicare and Medicaid patients are not eligible
• Prescription must be for an FDA-approved indication
• Must be a resident of the United States, including Michigan
• Enrollment is annual and requires re-registration each plan year

Michigan patients who lose commercial insurance mid-year can transition directly to the PAP by contacting NovoCare at 1-833-NOVO-411. Bridging a patient from a savings card to PAP typically takes 5 to 10 business days; prescribers should write a 30-day emergency supply to cover the gap.

Research published in Health Affairs found that copay assistance cards for insulin reduced patient out-of-pocket spending by a mean of $42 per fill compared to no assistance, but did not lower total plan spending [10]. Michigan patients should be aware that some insurers apply copay accumulator adjustments (CAA) that prevent savings-card payments from counting toward the annual deductible. Check your plan's Summary of Benefits and Coverage for CAA language.

Compounded Insulin Degludec in Michigan: Legal Status and Costs

Compounded insulin degludec is legally available in Michigan through state-licensed 503A compounding pharmacies. A 503A pharmacy compounds drugs for individual patient prescriptions, as distinct from a 503B outsourcing facility that produces batch quantities. Michigan's Board of Pharmacy regulates 503A pharmacies under the Michigan Public Health Code, MCL 333.17748 [11].

The FDA does not approve compounded drugs for safety and efficacy in the same way it approves Tresiba. Compounded insulin degludec is not the same as Novo Nordisk's Tresiba; it is prepared from pharmaceutical-grade insulin degludec bulk drug substance by a compounding pharmacy. Patients and providers should understand this distinction before switching.

Cost is the main reason patients pursue compounded formulations. Michigan 503A compounding pharmacies currently offer insulin degludec at prices ranging from $0 (through certain membership or telehealth programs) to approximately $50 per month, compared to the $510 list price for branded Tresiba. That cost difference can be clinically meaningful for uninsured or underinsured Michigan patients whose A1C is above target primarily because of cost-related insulin rationing.

A 2019 study in Diabetes Care found that 25% of insulin-dependent adults rationed insulin due to cost, with higher rates among those earning under $35,000 annually [12]. Michigan has a state-specific insulin cost-sharing law under Public Act 101 of 2020, which caps insulin copays at $50 per 30-day supply for state-regulated commercial insurance plans. This cap applies to brand-name Tresiba when covered by a Michigan-regulated plan, further reducing the cost advantage of compounded alternatives for insured patients [13].

Prescribers must write compounded insulin degludec on a standard prescription pad with the drug name, concentration, quantity, and patient-specific instructions. The prescription cannot be for a compounded product that is essentially a copy of a commercially available drug under FDA guidance, but clinical exceptions exist when a patient has a documented allergy to an excipient in the branded product or needs a concentration not commercially available [14].

Telehealth Prescribing of Tresiba in Michigan

Michigan permits telehealth prescribing of Tresiba. State law and the Michigan Public Health Code allow licensed Michigan physicians, nurse practitioners, and physician assistants to prescribe Schedule III-V controlled substances and non-controlled prescription drugs via synchronous telehealth without a prior in-person visit, as long as the provider-patient relationship is properly established [15].

Tresiba is not a controlled substance. It requires a valid prescription but no DEA schedule designation. A Michigan-licensed prescriber can conduct an audio-video telehealth visit, review the patient's glucose logs and A1C results (sent electronically before the visit), and transmit a Tresiba prescription directly to the patient's preferred Michigan pharmacy or to a compounding pharmacy that ships within the state.

HealthRX providers conduct this process routinely. A typical telehealth initiation visit covers current glycemic control, hypoglycemia history, injection technique, dose titration planning, and insurance/cost discussion. The American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm recommends basal insulin initiation at 10 units or 0.1, 0.2 units/kg daily, titrating by 2 units every 3 days until fasting glucose targets are met [16]. That titration protocol is fully manageable via follow-up telehealth visits or secure messaging.

Michigan telehealth prescribers must be licensed in Michigan or hold a valid interstate license recognized under Michigan's participation in the Interstate Medical Licensure Compact (IMLC). Patients should confirm their telehealth provider's Michigan license number via the Michigan LARA license search before the visit [17].

Dose, Administration, and Storage: What Michigan Patients Need to Know

Tresiba is injected subcutaneously once daily at any time of day, with the flexibility to shift the injection time by up to 8 hours if needed. This flexibility is a pharmacodynamic consequence of the ultra-long half-life, which the FDA label describes as exceeding 25 hours at steady state [2]. Injection sites include the abdomen, thigh, or upper arm; rotate sites to prevent lipohypertrophy.

The starting dose for insulin-naive type 2 diabetes patients is typically 10 units once daily, per both the FDA label and AACE 2023 guidelines [16]. For patients transferring from another basal insulin, the conversion is unit-to-unit from insulin glargine U-100 or insulin detemir, administered once daily. Patients switching from twice-daily detemir should convert by using 80% of the total daily detemir dose as the starting degludec dose, then titrate based on fasting glucose [2].

Storage: unopened Tresiba pens should be refrigerated at 36, 46°F (2, 8°C). Once a pen is in use, it can be stored at room temperature below 86°F (30°C) for up to 56 days. Michigan's seasonal temperature extremes matter here: in summer, an insulin pen left in a vehicle can exceed 86°F within 30 minutes. A 2020 study in PLOS ONE found that insulin stored above 37°C for even one hour showed measurable degradation in potency [18]. Michigan patients should use an insulated travel case with a refrigerant pack during warm months.

Hypoglycemia is the primary adverse effect. The DEVOTE trial showed a rate of 0.60 severe hypoglycemic episodes per patient-year with degludec vs. 1.05 per patient-year with glargine U-100 (RR 0.60; P<0.001) [3]. Michigan patients with chronic kidney disease (CKD), erratic meal timing, or alcohol use disorder face elevated hypoglycemia risk and should be counseled on glucagon rescue kits (intranasal glucagon, 3 mg, is available without a prescription at Michigan pharmacies under standing orders in several counties).

Comparing Tresiba to Other Basal Insulins Available in Michigan

Michigan patients and prescribers often compare Tresiba to three other basal options: insulin glargine U-300 (Toujeo), insulin glargine U-100 (Lantus, Basaglar), and insulin detemir (Levemir). Each has a different cost structure, action profile, and formulary tier.

A 2021 network meta-analysis in Diabetes, Obesity and Metabolism (N=17 trials, 12,390 participants) found that insulin degludec produced significantly fewer nocturnal hypoglycemic events compared with glargine U-100 (RR 0.75 to 95% CI 0.64, 0.88) and fewer overall hypoglycemic events compared with detemir (RR 0.82 to 95% CI 0.71, 0.95) [19]. Glycemic control (A1C reduction) was statistically equivalent across all four agents in that analysis.

Cost comparison in Michigan for uninsured patients in 2026:

• Insulin glargine U-100 (Basaglar biosimilar): approximately $50, $80 per month cash
• Insulin glargine U-300 (Toujeo): approximately $400, $450 per month list; cash pay varies
• Insulin detemir (Levemir): approximately $300, $350 per month list
• Tresiba (degludec): approximately $35 per month with savings programs

For Michigan Medicaid patients, the preferred formulary agent is typically insulin glargine U-100 (Basaglar is preferred over Lantus in most MCOs due to cost). Tresiba requires PA, as noted above, which means some patients face prescriber burden even when they have a strong clinical case [4].

The Endocrine Society's 2022 Clinical Practice Guideline on Diabetes Pharmacotherapy states: "We suggest insulin degludec over insulin glargine U-100 in adults with type 1 or type 2 diabetes who experience frequent nocturnal hypoglycemia" [20]. That suggestion carries a grade B recommendation and is citable in Michigan Medicaid PA appeals.

Where to Fill a Tresiba Prescription in Michigan

Michigan has more than 2,100 retail pharmacies licensed with the Michigan Board of Pharmacy. Major chains with consistent Tresiba inventory include:

• CVS (statewide, including 24-hour locations in Detroit, Grand Rapids, Lansing)
• Walgreens (statewide)
• Meijer (Michigan-headquartered; strong inventory in mid-Michigan and West Michigan)
• Kroger (statewide)
• Sparrow/Michigan Medicine outpatient pharmacies (for patients of affiliated health systems)

Independent compounding pharmacies licensed for 503A operations and capable of dispensing compounded insulin degludec include several in the Ann Arbor, Detroit, and Grand Rapids metro areas. Patients should verify 503A licensure directly with the Michigan Department of Licensing and Regulatory Affairs (LARA) before using any compounding pharmacy [11].

Mail-order options through PBM specialty pharmacies (Express Scripts, CVS Caremark, OptumRx) may offer 90-day supplies at a lower per-unit cost for commercially insured patients. A 90-day fill of Tresiba through a mail-order pharmacy with a Tier 3 copay typically costs $90, $180 depending on the plan, compared to $45, $90 per 30-day retail fill.

Michigan's prescription drug price transparency law (Public Act 260 of 2020) requires PBMs to report net drug spending to the state annually, but does not require pharmacies to post cash prices online. Patients can use GoodRx.com or NeedyMeds.org to obtain current cash-pay prices at specific Michigan zip codes before deciding where to fill [21].